INTRODUCTION
Organ bud progenitor cells, which have the remarkable capacity for rapid cell growth and differentiation into multi-lineage cells, play important roles in organ development. The hepatic progenitor cells (HPCs), or liver bud progenitors, specify from foregut endoderm at the embryonic day (E)9.5 in mice, followed by massive HPC expansion with a 10 4 -fold population doubling from E9.5 to E13.5 in mice (Koike et al., 2014; Takebe et al., 2013) . This tremendous growth is regulated by signals secreted from neighboring mesenchyme, such as HGF (Matsumoto et al., 2001) , BMPs (Rossi et al., 2001) and FGFs (Serls et al., 2005) , and by transcriptional networks that act intrinsically in the HPCs, such as Tbx3 (Suzuki et al., 2008) , Smad2/3 (Weinstein et al., 2001 ) and beta-catenin (Micsenyi et al., 2004 ). Yet, the mechanism regulating this intensive and transient amplification in developing liver bud is largely unknown.
Emerging studies of stem cell metabolism have elucidated a role for cell-type specific metabolic pathways that are modulated during proliferation, differentiation or reprogramming processes (Ito and Suda, 2014; Shyh-Chang et al., 2013a) . For instance, embryonic stem cells (ESC) generally utilize the glycolytic system as a self-renewing propagation process (Kim et al., 2006) , whereas differentiating ESC shift their metabolism to oxidative phosphorylation (Folmes et al., 2012) . Consistently, during the cellular reprograming process to induced pluripotent stem cells (iPSC), glycolytic metabolism transitions from dependence on oxidative phosphorylation in adult fibroblast (Bukowiecki et al., 2014) . The pivotal role of unique amino acid metabolism is also reportedly shown to maintain the pluripotency. Indeed, starvation of Thr, Met, Cys or Gln abolished mouse or human PSC growth in culture (Shiraki et al., 2014; Shyh-Chang et al., 2013b; Tohyama et al., 2016) . Thus, the mechanism of energy creation is diverse depending on each cell/tissue types and its differentiation state. However, little is known about the metabolic dynamics during the early growth phase of hepatogenesis.
The aim of this study was to identify the metabolic demands of rapid hepatic progenitor growth phase during mouse liver bud development and study their modulatory effects on ex vivo expansion by defined culture medium. Furthermore, in order to address the human specific metabolic dynamics during early growth phase of hepatogenesis, we took advantage of our recently developed liver bud organoid model from human iPSC (hiPSC) (Takebe et al., 2013 ) so as to determine if the implied metabolic mechanism is conserved in humans.
(Bcat)1 was strongly expressed in early fetal liver cells (E9.5, 10.5 and 11.5), and suppressed in later developmental stages of the liver (Table S3 and Fig. 1B ). qRT-PCR analysis confirmed the highest expression of Bcat1 in HPCs of E11.5 and E13.5 livers (Fig. 1C) . Immunofluorescent analysis revealed specific Bcat1 protein localization in liver compared with other tissues at E11.5 ( Fig. 1D and Fig. S1 ). Collectively, our developmental transcriptome data suggested the specific activation of Bcat1 gene during early HPC expansion phase.
Aminotransferase enzymes Bcats catalyze the first step in BCAA (valine, leucine and isoleucine) metabolism to form branched chain alpha-keto acids (BCKAs) and glutamate ( Fig. 2A) . Subsequent reactions convert the BCAA derivatives into acetyl-CoA or succinyl-CoA that enter the citric acid cycle. In order to elucidate metabolite production in the BCAAs related pathway, we performed metabolome analysis using E11.5, 19.5 and 8 weeks mouse liver tissues. We found that the actual concentrations of BCAAs at E9.5 were lower than those of 8-week-old mouse liver ( Fig. 2A) .
Then, pregnant mice were fed BCAA depleted diets on E8.5-13.5 gestation in order to investigate the importance of dietary BCAAs supply for early hepatogenesis in the fetuses. We found that the relative liver weight per whole body was decreased with non-BCAA-containing diets by 54.0 ± 16.7 % of control mice (Fig.   2B , C). Furthermore, similar liver hypoplasia was also observed in mice fed L-valine depleted diets (Fig. S2 ).
These results suggest active BCAA metabolism in developing liver bud relative to the more mature stages.
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To further dissect the mechanism of liver bud defects, we performed flow cytometry analysis to evaluate the effects on HPCs. Liver cells for E13.5 fetal mice given L-valine depleted diets were analyzed by hematopoietic cell marker, CD45/TER119 (Kawamoto et al., 2000; Kina et al., 2000) and HPC marker, Dlk1 (Tanimizu et al., 2003) . Dlk1+ HPC populations were decreased to 81.7 ± 13.9 % for L-valine depleted diets ( Fig. 2D , E), whereas the hematopoietic lineages were not affected by this nutrition. These results suggested that active dietary BCAAs by Bcats is essential for fetal liver bud growth presumably due to failure of HPC expansion.
To test if BCAA affects HPC growth, the proliferative capacity of HPCs from various developmental stages was examined using clonogenicity assay in vitro in the presence of BCAA supplements.
Isolated fetal liver cells attached to the laminin-coated plates under a clonal condition to assess their colony formation capability. Using liver cells from E11.5, 13.5 and 15.5, we found that highly proliferative colonies comprised of more than 90 cells were 30.9 ± 10.0 % increased in E11.5 liver cell by 4.0 mM of L-valine supplementation, but not increased in E13.5 nor E15.5. The other types of amino acids or their combinations did not stimulate the colony expansion in E11.5 liver bud cells (Fig. 3C, D) . A dose escalation study of L-valine demonstrated that the number of highly clonogenic colonies from E11.5 fetal liver proportionally increased 4.0mM out of 0.4 mM, 0.8 mM and 4.0 mM conditions (Fig. S3 ). The addition of 4.0 mM of L-valine to medium did not affect the bi-potent differentiation capacity for hepatic lineage cells identified by albumin and Ck7 co-immunostaining analysis (Fig. 3E, F) . These results suggested that L-valine supplementation promotes murine HPC expansion with sustained bi-directional differentiation capacity.
To determine the relevance of L-valine for human liver bud growth, we employed a previously established three dimensional (3-D) liver bud (LBs) organoid model (Takebe et al., 2013) (Fig. 4A) Fig. 4C and Fig. S4A ), which is estimated to be approximately 2-fold increase of hiPSC-derived HPCs in cell number per LB. As the modulatory effects of stromal lineages remains minimal (Fig. S4B) , it is suggested that unique L-valine metabolism by BCAT1 is conserved both in human and mouse during liver bud development, highlighting the potential of L-valine nutritional approach for modulating human fetal liver bud growth.
Next, we examined whether the BCAA effect is specific to human HPC in LB by assessing isolated cell culture. To examine the direct effects of amino acids, hiPSC-derived HPCs expressed the high levels of
BCATs (Fig. S4C , D) and were cultured in the BCAAs-supplemented medium (Fig. 4D ). Similar to mouse HPC culture, 4.0 mM L-valine supplemented HPCs significantly increased cell proliferation compared with cells grown in a control (Fig. 4E) . On the other hand, the expressional profiling of number of genes were not affected by L-valine supplementation including various stage specific markers, such as NANOG, FOXA2, SOX17, AFP, ALB, SOX7 suggesting the maintenance of the HPC differentiation status by L-valine supplementation (Fig.   S4E ). To further investigate whether the L-valine supplemented culture medium could expand hiPSC-HPCs via several passages, we performed subsequent re-plating culture. L-valine treated hiPSC-HPCs maintained their rigorous proliferative capacity even after three passages (Fig. 4F ). Furthermore, hepatocyte marker genes, such as ALB, RBP4 and ASGR1, in expanded hiPSC-HPCs by several passages were induced after hepatic differentiation of amplified HPC. These results suggested that L-valine supplementation effectively propagates hiPSC-HPCs similar to mouse by preserving its bi-potent differentiation capability, leading to a future mass production strategy by expanded HPC with the ability for differentiation into hepatocyte like cells (Fig. 4G ).
Organoid technology paved a way for modeling human disease and development and ultimately regenerative therapy. However, identifying a missing cue to recapitulate massive organ bud expansion processes that naturally occur during embryogenesis, remains a major challenge. , 2016; Tohyama et al., 2013) . These novel approaches are expected to aid in establishing a safer cell source free of undesired lineages from hPSCs, which enhances safety during stem cell therapy with a simple and low-cost method (Tohyama et al., 2016) . Collectively, such a distinguishing feature of HPC metabolism will be able to promote the pluripotent stem cell derived HPC expansion for economical mass production of human liver buds, thereby, facilitating a realistic application of iPSC-derived organoids towards therapy.

Materials and methods
Animals
C57BL/6 mice were purchased from Japan SLC (Japan). All animal experiments in this study were performed under approval from the institutional animal care and use committee of Yokohama City University (Approval Number: 11-63). Further details can be found in the supplementary M&M.
Cell culture
hiPSCs (TkDA3-4; kindly provided by Dr Nakauchi at the University of Tokyo) maintenance and organoid formation was performed as described previously (Takebe et al., 2013) . Briefly, to induce human liver bud formation in vitro, hiPSC-derived HPCs, HUVECs and human MSCs were cocultured in the presence of indicated BCAAs, and plated on EZSPHERE plate (Nacalai, Japan).
Transcriptome and metabolome analysis
Acquisition of transcriptome and metabolome profiles was performed as described previously (Takebe et al., 2013) . Further details can be found in the supplementary methods.
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Statistical analysis
Data are expressed as the means ± s.d. from the number of repeated independent experiments described in each figure legend. Comparisons between three or four groups were analyzed using the Mann-Whitney's U test.
Two-tailed P values of <0.05 were considered significant.
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SUPPLEMENTAL MATERIALS AND METHODS
Animals
For experiments using amino acid depleted diets, mice were mated and vaginal plugs identified the following morning. Plugged females were naturally fed BCAAs or valine depleted diets from gestational day 8 and harvested at day 13 to dissect fetal liver tissue for assessing HPC frequency.
For preparation of fetal liver cells, the tissues were acquired from fetal mice at embryonic day (E) 9.5, 10.5, 11.5, 13.5, 15.5, 17.5, 19.5. The livers from E9.5, 10.5, 11.5, 13.5 and 15.5 were dissociated by treating them with DMEM/F12 (Life technologies, USA) containing 0.2% trypsin (Life technologies) and 5% fetal bovine serum (FBS: MP Biomedicals, USA) by shaking at 37°C
for 15 minutes. The livers from E17.5 and 19.5 were dissociated by treating with 0.1% collagenase solution. After pipetting and being washed, cells were triturated and passed through 40 μm nylon meshes to obtain a single-cell suspension.
Cell culture
For mouse cell culture, E11.5, 13.5 and 15.5 mouse fetal liver cells were seeded on laminin- 
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Undifferentiated human iPSCs were maintained without feeder cells in mTeSR1 medium (STEMCELL Technologies). For differentiation, iPSCs were seeded onto a Matrigel (Growth factor reduced; Corning) coated dish, and the medium was replaced with RPMI1640 medium (Wako) containing 1% B-27 supplement minus insulin (Gibco) and Human activin A (100 ng/mL; R&D Systems) for 6 days. The cells were further treated with RPMI1640 containing 1% B27 supplement (Gibco), bFGF (10 ng/mL; R&D systems) and BMP4 (20 ng/mL; R&D systems) for 3 days. After 9 days of differentiation, generated cells, which were comparable to HPCs, were passaged to laminin coated 6-well plates (5 x 10 4 cells per well) and then cultured in RPMI1640 containing 1% B27 supplement with addition of BCAAs for 6 days.
Human umbilical vein endothelial cells (HUVECs: Lonza) and human mesenchymal stem cells (MSCs: Lonza) were maintained in endothelial growth medium (EGM: Lonza) or MSC growth medium (Lonza). Cells were incubated at 37°C in a humidified atmosphere of 5% CO2. The relative quantification of gene expression was carried out according to the delta-delta Ct (threshold cycle) method. Gapdh and Eukaryotic 18S rRNA was chosen as a reference endogenous control. Mouse and human-specific primer sequences (forward and reverse) are for 10 min, 95°C for 15 s, and 60°C for 1 min for a total of 45 cycles.
Staining and image analysis
For microarray analysis, total RNA of fetal liver excluded hematopoietic cells was isolated using
TRIzol Reagent (Life Technologies, CA, USA). For quality control of total RNA samples, Agilent 2100 Bioanalyzer was used. Expression profiling was obtained with Whole Mouse
Genome 4x44K v2 OligoDNA Microarray Kit (Agilent Technologies) according to manufacturer's instruction. Hybridization signals were scanned and processed by 75% percentile shift normalization using GeneSpring GX11.5.1 software.
For Metabolome analysis, collected mouse liver tissues from several time points of developmental process were analyzed by Human Metabolome Technologies (Japan). Mouse liver sample and methanol including 50 μM of internal standard material were put into the tube on ice to fracture by crushing machine. Chloroform and water were added to the sample and centrifuged to isolate the aqueous layer. After ultrafiltration of isolated layer, pellet was resuspended in water. Acquisition of metabolome profiles was performed as described previously (Takebe et al., 2013) . CE-TOFMS was carried out using an Agilent CE Capillary Electrophoresis Reverse  mBcat1  CTGGATAAACGAAGACGGAGA  CACTCCTGGGAGAATGATGC  mBcat2  GTCGGTGACTGCAAGTTGG  CTCAGTGAGCTGGTGGTCTG  mAlb  CTTTGCAATGGATGCTCTCTT  TTCTCCTTCACACCATCAAGC  mKrt7  GGAGATGGCCAACCACAG  GGCCTGGAGTGTCTCAAACTT  hBCAT1  GATGTTTGGCTCTGGTACAGC  GGACCATTCTCCATAGTTGGAA  hALB  GTGAGGTTGCTCATCGGTTT  GAGCAAAGGCAATCAACACC  hRBP4  CCAGAAGCGCAGAAGATTG  TTTCTTTCTGATCTGCCATCG  hASGR1  GCTGGAGAAACAGCAGAAGG  CGCAGGTCAGACACGAACT  hNANOG  GAGATGCCTCACACGGAGAC  AGGGCTGTCCTGAATAAGCA  hFOXA2  CGTTCCGGGTCTGAACTG  ACCGCTCCCAGCATACTTT  hSOX17  ACGCCGAGTTGAGCAAGA  TCTGCCTCCTCCACGAAG  hAFP  TGTACTGCAGAGATAAGTTTAGCTGAC  TCCTTGTAAGTGGCTTCTTGAAC  hSOX7 TTCCTCACCAGCCAGGTC ATTTGCGGGAAGTTGCTCTA 
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SUPPLEMENTAL DISCUSSSION
During the early phase of organogenesis, several animal studies indicated the importance of maternal nutrition for fetal stage critical events regarding gastrointestinal tract development including expansion, differentiation and vascularization. Fetuses subjected to nutrient restriction during early to mid-gestation have decreased growth of the gastrointestinal tract including liver (Duarte et al., 2013; Wang et al., 2008) . In humans, maternal dietary amino acid supplementation to improve fetal growth has been considered as an option to prevent or treat intrauterine growth restriction, as the specific amino acid transport system can transfer all of the BCAAs (Brown et al., 2011) . However, the primary therapeutic time-window is significantly limited from mid-to late-gestational stages in humans due to a lack of human predictive model.
As examined in our study, the application of our recently developed human PSC-organoid model will be a novel alternative to assess the benefit of nutritional intervention in culture before entering clinical application. Future studies of BCAA supplementation will aid in developing an effective nutritional strategy for promoting liver bud growth during the early phase of pregnancy.
One remaining question in our studies is whether the importance of BCAA nutritional effect for progenitor growth is specific to HPC or not. Comparing our results of the impairment of HPC expanding capability by direct BCAA deprivation in vitro, the effect size of in vivo maternal dietary deprivation seemed significant by far. This observed discrepancy may be attributed to: (1) secondary effects of the other HPC supportive progenitors affected in vivo, or (2) the culture system does not accurately reflect the physiological condition in vitro. Previous rat studies confirmed the former interpretation because fetal systemic growth could be affected by administration of BCAA combined with caloric restriction (Brown et al., 2011) . Additionally, collective evidence suggested that amino acid or glucose metabolism is important for
